Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 202

Similar articles for PubMed (Select 21504985)

1.

Drug repositioning for orphan diseases.

Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, Jegga AG.

Brief Bioinform. 2011 Jul;12(4):346-56. doi: 10.1093/bib/bbr021. Epub 2011 Apr 18. Review.

2.

The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?

Wellman-Labadie O, Zhou Y.

Health Policy. 2010 May;95(2-3):216-28. doi: 10.1016/j.healthpol.2009.12.001. Epub 2009 Dec 29.

PMID:
20036435
3.

Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.

Xu K, Coté TR.

Brief Bioinform. 2011 Jul;12(4):341-5. doi: 10.1093/bib/bbr006. Epub 2011 Feb 26.

4.

Drugs for rare diseases: mixed assessment in Europe.

[No authors listed]

Prescrire Int. 2007 Feb;16(87):36-42.

PMID:
17323539
5.

In silico repositioning of approved drugs for rare and neglected diseases.

Ekins S, Williams AJ, Krasowski MD, Freundlich JS.

Drug Discov Today. 2011 Apr;16(7-8):298-310. doi: 10.1016/j.drudis.2011.02.016. Epub 2011 Mar 1. Review.

PMID:
21376136
6.

Developing treatments for inborn errors: incentives available to the clinician.

Haffner ME.

Mol Genet Metab. 2004 Apr;81 Suppl 1:S63-6.

PMID:
15050976
7.
8.

Drug development for exceptionally rare metabolic diseases: challenging but not impossible.

Putzeist M, Mantel-Teeuwisse AK, Wied CC, Hoes AW, Leufkens HG, de Vrueh RL.

Orphanet J Rare Dis. 2013 Nov 15;8:179. doi: 10.1186/1750-1172-8-179.

9.

What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.

Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, Imoisili MA.

Pediatrics. 2012 Mar;129(3):516-21. doi: 10.1542/peds.2011-1798. Epub 2012 Feb 27.

10.

The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.

Burke KA, Freeman SN, Imoisili MA, Coté TR.

Clin Pharmacol Ther. 2010 Oct;88(4):449-53. doi: 10.1038/clpt.2010.193. Review.

PMID:
20856241
11.

Clinical pharmacology as a cornerstone of orphan drug development.

Bashaw ED, Huang SM, Coté TR, Pariser AR, Garnett CE, Burckart G, Zhang L, Men AY, Le CD, Charlab R, Gobburu JV, Lesko LJ.

Nat Rev Drug Discov. 2011 Oct 31;10(11):795-6. doi: 10.1038/nrd3595. Review.

PMID:
22037026
12.

Issues surrounding orphan disease and orphan drug policies in Europe.

Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S.

Appl Health Econ Health Policy. 2010;8(5):343-50. doi: 10.2165/11536990-000000000-00000.

PMID:
20804226
13.

"Creating hope" and other incentives for drug development for children.

Connor E, Cure P.

Sci Transl Med. 2011 Jan 19;3(66):66cm1. doi: 10.1126/scitranslmed.3001707.

PMID:
21248312
14.

Rare diseases, orphan drugs and their regulation: questions and misconceptions.

Tambuyzer E.

Nat Rev Drug Discov. 2010 Dec;9(12):921-9. doi: 10.1038/nrd3275. Epub 2010 Nov 9.

PMID:
21060315
15.

Translation of rare disease research into orphan drug development: disease matters.

Heemstra HE, van Weely S, Büller HA, Leufkens HG, de Vrueh RL.

Drug Discov Today. 2009 Dec;14(23-24):1166-73. doi: 10.1016/j.drudis.2009.09.008. Epub 2009 Oct 7. Review.

PMID:
19818412
16.

Orphan drug development: an economically viable strategy for biopharma R&D.

Meekings KN, Williams CS, Arrowsmith JE.

Drug Discov Today. 2012 Jul;17(13-14):660-4. doi: 10.1016/j.drudis.2012.02.005. Epub 2012 Feb 17.

PMID:
22366309
17.

A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.

Liu BC, He L, He G, He Y.

J Public Health Policy. 2010 Dec;31(4):407-20; discussion 420-1. doi: 10.1057/jphp.2010.30.

PMID:
21119648
18.

Predictors of orphan drug approval in the European Union.

Heemstra HE, de Vrueh RL, van Weely S, Büller HA, Leufkens HG.

Eur J Clin Pharmacol. 2008 May;64(5):545-52. doi: 10.1007/s00228-007-0454-6. Epub 2008 Jan 22.

19.

When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.

Herder M.

Account Res. 2013;20(4):227-69. doi: 10.1080/08989621.2013.793120.

PMID:
23805831
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk